Showing results (61-70 of 457) with videos related to
Sort By:
Pageof 46
Annals of the Rheumatic Diseases|April 27, 2013
From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trialsRobert Landewé, Vibeke Strand, Désirée van der HeijdeLupus|January 8, 2021
Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 yearsMitra Moazzami, Vibeke Strand, Jiandong Su, et al.RMD Open|July 19, 2018
Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activityGeorge A Karpouzas, Vibeke Strand, Sarah R OrmsethDrugs|February 2, 2026
Nanoencapsulated Sirolimus Plus Pegadricase (NASP) in Uncontrolled Gout: Current Status and Future DirectionsHerbert S B Baraf, Naomi Schlesinger, Vibeke StrandRheumatology and Therapy|March 3, 2017
Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of AbataceptLaure Gossec, Souhila Ahdjoudj, Evo Alemao, et al.Arthritis and Rheumatism|November 13, 2003
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trialAllan Gibofsky, Gary W Williams, Frank McKenna, et al.Annals of the Rheumatic Diseases|January 16, 2016
The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritisAtul Deodhar, Vibeke Strand, Jonathan Kay, et al.Clinical Therapeutics|August 19, 2007
Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled studyAllan Gibofsky, Jude Rodrigues, Justus Fiechtner, et al.Expert Opinion on Drug Safety|May 26, 2015
Low-dose SoluMatrix diclofenac : a review of safety across two Phase III studies in patients with acute and osteoarthritis painAllan Gibofsky, Roy Altman, Stephen Daniels, et al.Current Medical Research and Opinion|October 28, 2015
Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 studyRoy Altman, Marc Hochberg, Allan Gibofsky, et al.Pageof 46